Cargando…
Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases
BACKGROUND: The development of a clinically useful fibroblast growth factor 21 (FGF21) hormone has been impeded by its inherent instability and weak FGF receptor (FGFR) binding affinity. There is an urgent need for innovative approaches to overcome these limitations. METHODS: We devised a structure-...
Autores principales: | Zhao, Longwei, Niu, Jianlou, Lin, Huan, Zhao, Jing, Liu, Yang, Song, Zihui, Xiang, Congshang, Wang, Xiaojie, Yang, Yong, Li, Xiaokun, Mohammadi, Moosa, Huang, Zhifeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838362/ https://www.ncbi.nlm.nih.gov/pubmed/31631034 http://dx.doi.org/10.1016/j.ebiom.2019.09.052 |
Ejemplares similares
-
Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects
por: Ying, Lei, et al.
Publicado: (2021) -
Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
por: Zhao, Longwei, et al.
Publicado: (2017) -
Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid
por: Lin, Huan, et al.
Publicado: (2019) -
Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer
por: Suh, Jae Myoung, et al.
Publicado: (2014) -
Editorial: Endocrine and Paracrine Role of FGF23 and Klotho in Health and Disease
por: Erben, Reinhold G.
Publicado: (2019)